A Nationwide Cross-Sectional Study of Self-Reported Adherence and Factors Associated with Analgesic Treatment in People with Chronic Pain.

This study aims to shed light on the frequency and associated factors of self-reported adherence to analgesic treatment among chronic pain (CP) patients in the Spanish population. A nationwide cross-sectional study was performed of 1066 Spanish adults, of whom 251 suffered from CP and 168 had been prescribed analgesic treatment. Adherence was assessed using a self-reported direct questionnaire and related factors were collected. Descriptive and bivariate analyses were conducted. Among the 23.5% (95% CI: 21.0-26.2%) of the sample with CP, 66.9% (95% CI: 60.7-72.7%) were taking analgesic treatment prescribed by a doctor, and 81.0% (95% CI: 74.2-86.6%) said they took the treatment as the doctor indicated. However, 17.6% forgot to take the medication, 11% overused them when in great pain, 46.3% stopped the treatment when feeling better and 33.3% when feeling worse, and 7.3% stopped taking them for financial reasons. Higher intensity of pain, polymedication, administration route (injection/patches) and some patient-related factors were associated with self-perceived adherence to treatment. Most Spanish people with CP consider that they are adherent to their analgesic treatment. However, their behavior presents contradictions. It would be advisable for professionals to inform patients about appropriate behavior regarding their therapy recommendations, and to explore potential factors related to non-adherence. This could contribute to improving pain control.

Relationship between diabetic neuropathic pain and comorbidity. Their impact on pain intensity, diabetes complications and quality of life in patients with type-2 diabetes mellitus.

OBJECTIVE: To compare cognitive function, mood and sleep status in patients with and without diabetic neuropathic pain (DNP) and their relationship with pain intensity, diabetes complications, and quality of life. To determine whether these relationships differ depending on the sensorial phenotype. METHODS: Cross-sectional study performed on patients with type-2 diabetes-mellitus and neuropathy. Presence of DNP, pain intensity and phenotype, mood status, sleep characteristics and quality of life were measured. RESULTS: A total of 130 patients (65 with DNP) were included. DNP was related to poor sleep quality (OR = 1.03;CI95%:1.02-1.05), pain treatment (OR = 3.00,CI95%:1.24-7.29) or previous anxiety (OR = 2.70,CI95%:1.05-6.99). Patients with specific phenotypes or depression (=0.82,CI95%:-0.02-1.67) referred more severe pain. More complications were related to older age (OR = 1.40,CI95%:1.12-1.66), higher pain intensity (OR = 1.51,CI95%:1.00-2.28), lower cognitive performance (OR = 1.25,CI95%:1.09-1.43), previous anxiety (OR = 10.48,CI95%:1.46-75.24) and insulin treatment (OR = 124.50,CI95%:6.64-2335.06). Decrease in mental quality of life was associated with sleep disorders (ß = -0.33,CI95%:-0.48,-0.23), physical comorbidities (ß = -9.73,CI95%:-18.15, -1.31) and previous anxiety (ß = -7.91,CI95%:-13.04, -2.77). Lower scores in physical quality of life were related to sleep disorders (ß = -0.12,CI95%:-0.21, -0.18), obesity (ß = -8.35,CI95%:-13.16, -3.55), longer time since diagnosis (ß = -0.72,CI95%:-1.44;0.01) and disability (ß = -14.58,CI95%:-24.69; -4.48). CONCLUSIONS: The results support the idea that mental comorbidity and sleep disorders are factors associated with DNP and greater pain intensity, more diabetes complications and lower quality of life. Moreover, they highlight the relationship between sensorial phenotypes and pain intensity, and lower cognitive performance and diabetes complications.

Anxiety, depression and sleep disorders in patients with diabetic neuropathic pain: a systematic review.

Introduction: Diabetic neuropathic pain (DNP) is a disabling complication suffered by patients with diabetic neuropathy. DNP coexists with different conditions, especially mental and sleep disorders, which seem to impair the management and course of the disease. However, there is a lack of accurate results about their prevalence. Consequently, the authors analyze the prevalence of anxiety, depression and/or sleep disorders in DND patients.Areas covered: Among the 206 articles found in the search, 8 studies with data from 5 different countries fulfilled the inclusion criteria. The prevalence of anxiety reported ranged between 7.8%-60.4% and that of depression between 13.6%- 50.6%. The two conditions coexist in 26.4%-30.6% in DND patients. A higher prevalence was found when the information was obtained using scales than when it came from medical records. The prevalence of sleep disorders found ranged from 41.6%-43.8%. However, there is lack of information about and the results are often expressed using the mean scores of the scales.Expert opinion: Although the data in the literature vary, a high prevalence of anxiety, depression and sleep comorbidities exists among patients with DNP. These results reaffirm the need to perform systematic evaluations and to identity their presence using validated instruments to obtain more reliable results.